Search

Your search keyword '"Jonas, Sven"' showing total 614 results
Start Over Author "Jonas, Sven"
614 results on '"Jonas, Sven"'

4. Grundlagen der gastrointestinalen Tumorerkrankungen

Author

Schmelzle, Moritz, Jonas, Sven, Strumberg, Dirk, Kaufmann, Astrid, Aretz, Stefan, Pietsch, Uta-Carolin, Kaisers, Udo X., Monz, Katharina, Hartmann, Karl-Axel, Hübner, Jutta, Lordick, Florian, Raida, Martin, Winter, Andreas, Burkholder, Iris, Edler, Lutz, Erckenbrecht, J.F., editor, and Jonas, Sven, editor

Published
2015
Full Text
View/download PDF

7. Entzündliche Erkrankungen des Dünn- und Dickdarms

Author

Lembcke, Bernhard, Schulze, Hermann, Dignaß, Axel, Scheuerlein, Hubert, Settmacher, Utz, Tromm, Andreas, Erckenbrecht, Joachim F., Jonas, Sven, Mirow, Lutz, Hildebrand, Philipp, Caspary, Wolfgang F., Stein, Jürgen, Erckenbrecht, J.F., editor, and Jonas, Sven, editor

Published
2015
Full Text
View/download PDF

11. Boerhaave’s Syndrome

Author

Gäbelein, Gereon, Benckert, Christoph, Eichfeld, Uwe, Jonas, Sven, Lumley, J.S.P., Series editor, Siewert, J. R., Series editor, Dienemann, Hendrik C., editor, Hoffmann, Hans, editor, and Detterbeck, Frank C., editor

Published
2015
Full Text
View/download PDF

17. The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation

Author

Gül-Klein, Safak, Schmitz, Paulina, Schöning, Wenzel, Öllinger, Robert, Lurje, Georg, Jonas, Sven, Uluk, Deniz, Pelzer, Uwe, Tacke, Frank, Schmelzle, Moritz, Pratschke, Johann, Ossami Saidy, Ramin Raul, and Eurich, Dennis

Subjects
reduced immunosuppression, liver transplantation, recurrent cholangiocellular carcinoma, cholangiocellular carcinoma, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Simple Summary: Oncological follow-up after liver transplantation for cholangiocellular carcinoma must consider the risk of recurrence. Immunosuppressive medication with so-called mTOR inhibitors seems to have a tumor-suppressive effect, as improved survival has been shown under this medication for patients with recurrent hepatocellular carcinoma after liver transplantation. The aim of our study was to investigate recurrence and survival in relation to tumor type and type of immunosuppression for cholangiocellular carcinoma after liver transplantation. The time from liver transplantation to recurrence and survival after cancer recurrence were endpoints of the study. Significant improvement in survival for recurrent cholangiocellular carcinoma was seen after surgical resection and reduction in immunosuppression, while N1 status at transplantation and histological Grading >1 were associated with worse outcomes. Abstract: Liver transplantation (LT) for cholangiocarcinoma (CCA), or biliary tract cancer (BTC), remains controversial regarding high recurrence rates and poor prognosis. Oncological follow-up may benefit from tumor-inhibiting properties of mTOR inhibitors (mTORI), shown with improved survival for recurrent hepatocellular carcinoma (HCC) patients after LT. The aim of this study was to investigate the recurrence and survival in relation to tumor type and type of immunosuppression (IS). LT patients with CCA or mixed HCC/CCA (mHCC/CCA) (n = 67) were retrospectively analyzed. Endpoints were the time from LT to recurrence (n = 44) and survival after recurrence. Statistically significant impairment in survival for recurrent CCA (rCCA) was shown in patients not eligible for surgical resection (HR 2.46 (CI: 1.2-5.1; p = 0.02). Histological proven grading >1 and N1 status at initial transplantation were associated with impaired survival (HR 0.13 (CI: 0.03-0.58); p < 0.01 and HR 3.4 (CI: 1.0-11.65); p = 0.05). Reduced IS after tumor recurrence improved survival (HR 4.2/CI: 1.3-13.6; p = 0.02). MTORI initiation before recurrence or after had no significant impact on survival. Our data thereby indicate, similar to findings in recurrent HCC after LT, that patients with rCCA after LT benefit from a reduction in IS upon recurrence.

Published
2022

22. Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation : Results From the Randomized HEPHAISTOS Trial

Author

Nashan, Björn, Schemmer, Peter, Pascher, Andreas, Becker, Thomas, Guba, Markus, Mueller, Volker, Perrakis, Aristotelis, Klempnauer, Juergen, Lehner, Frank, Weiss, Karl Heinz, Pollok, Joerg-Matthias, Manekeller, Steffen, Braun, Felix, Nadalin, Silvio, Jonas, Sven, Bartels, Michael, Seehofer, Daniel, Tautenhahn, Hans- Michael, Schlitt, Hans Juergen, Heise, Michael, Kaiser, Gernot, Klein, Christian Georg, Moench, Christian, Schlitt, Hans J., Ulrich, Frank, Schnitzbauer, Andreas, Fischer, Lutz, Neumann, Ulf Peter, Klein, Christian G., Kroeger, Irena, Wimmer, Peter, and Hephaistos Study Group

Subjects
Graft Rejection, medicine.medical_specialty, medicine.medical_treatment, Urology, Medizin, Renal function, Liver transplantation, Early initiation, Tacrolimus, medicine, Humans, Everolimus, Adverse effect, Transplantation, Hepatology, business.industry, Incidence (epidemiology), Significant difference, Graft Survival, Liver Transplantation, Surgery, business, Immunosuppressive Agents, medicine.drug, Glomerular Filtration Rate
Abstract

Everolimus-facilitated reduced-exposure tacrolimus (EVR + rTAC) at 30 days after liver transplantation (LT) has shown advantages in renal preservation. This study evaluated the effects of early initiation of EVR + rTAC in de novo LT recipients (LTRs). In HEPHAISTOS (NCT01551212, EudraCT 2011-003118-17), a 12-month, multicenter, controlled study, LTRs were randomly assigned at 7 to 21 days after LT to receive EVR + rTAC or standard-exposure tacrolimus (sTAC) with steroids. The primary objective was to demonstrate superior renal function (assessed by estimated glomerular filtration rate [eGFR]) with EVR + rTAC versus sTAC at month 12 in the full analysis set (FAS). Other assessments at month 12 included the evaluation of renal function in compliance set and on-treatment (OT) patients, efficacy (composite endpoint of graft loss, death, or treated biopsy-proven acute rejection [tBPAR] and individual components) in FAS, and safety. In total, 333 patients (EVR + rTAC, 169; sTAC, 164) were included in the FAS. A high proportion of patients was nonadherent in maintaining tacrolimus trough levels (EVR + rTAC, 36.1%; sTAC, 34.7%). At month 12, the adjusted least square mean eGFR was numerically higher with EVR + rTAC versus sTAC (76.2 versus 72.1 mL/minute/1.73 m2 , difference: 4.1 mL/minute/1.73 m2 ; P = 0.097). A significant difference of 8.3 mL/minute/1.73 m2 (P = 0.03) favoring EVR + rTAC was noted in the compliance set. Incidence of composite efficacy endpoint (7.7% versus 7.9%) and tBPAR (7.1% versus 5.5%) at month 12 as well as incidence of treatment-emergent adverse events (AEs) and serious AEs were comparable between groups. A lower proportion of patients discontinued EVR + rTAC than sTAC treatment (27.2% versus 34.1%). Early use of everolimus in combination with rTAC showed comparable efficacy, safety, and well-preserved renal function versus sTAC therapy at month 12. Of note, renal function was significantly enhanced in the compliance set.

Published
2022
Full Text
View/download PDF

23. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged‐release tacrolimus plus mycophenolate mofetil or sirolimus

Author

Rummo, Oleg O., Carmellini, Mario, Rostaing, Lionel, Oberbauer, Rainer, Christiaans, Maarten H. L., Mousson, Christiane, Langer, Robert M., Citterio, Franco, Charpentier, Bernard, Brown, Malcolm, Kazeem, Gbenga, Lehner, Frank, Heer, Munish, Lim, Wai, Mühlbacher, Ferdinand, Pratschke, Johann, Bonvoisin, Cathérine, Kuypers, Dirk, Dedochova, Jarmila, Kuman, Milan, Le Meur, Yann, Deteix, Patrice, Frimat, Luc, Lang, Philippe, Lebranchu, Yvon, Legendre, Christophe, Westeel, Pierre Francois, Schenker, Peter, Hilgers, KarlFriedrich, Witzke, Oliver, Hauser, Ingeborg, Kliem, Volker, Zeier, Martin, Kunzendorf, Ulrich, Bartels, Michael, Jonas, Sven, Guba, Markus, Wolters, Heiner H., Chan, TakMao, Caputo, Flavia, Sparacino, Vito, Nowicki, Michal, Glyda, Maciej, Kim, Yu Seun, Ha, Jongwon, Kim, Chan Duck, Han, Duck Jong, Kim, Yeong Hoon, Perlin, Dmitry, Salʼmayer, Alexander, Semchenko, Sergey B., Nesterenko, Igor, Franco, Antonio, Grinyó, Josep, Inza, Ainhoa, Ruiz, Juan Carlos, Chiang, YangJen, Lee, PoChang, Suleymanlar, Gultekin, Sevmis, Sinasi, and Kacar, Serdar

Published
2017
Full Text
View/download PDF

29. CD44 and CXCL9 serum protein levels predict the risk of clinically significant allograft rejection after liver transplantation

Author

Raschzok, Nathanael, Reutzel-Selke, Anja, Schmuck, Rosa Bianca, Morgul, Mehmet Haluk, Gauger, Ulrich, Prabowo, Kukuh Aji, Tannus, Laura-Marie, Leder, Annekatrin, Struecker, Benjamin, Boas-Knoop, Sabine, Bartels, Michael, Jonas, Sven, Lojewski, Christian, Puhl, Gero, Seehofer, Daniel, Bahra, Marcus, Pascher, Andreas, Pratschke, Johann, and Sauer, Igor Maximilian

Published
2015
Full Text
View/download PDF

36. Management of esophageal perforations

Author

Schmidt, Sven Christian, Strauch, Stefan, Rösch, Thomas, Veltzke-Schlieker, Wilfried, Jonas, Sven, Pratschke, Johann, Weidemann, Henning, Neuhaus, Peter, and Schumacher, Guido

Published
2010
Full Text
View/download PDF

44. Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation : Results From the Randomized HEPHAISTOS Trial

Author

Nashan, Björn, Schemmer, Peter, Braun, Felix, Schlitt, Hans J., Pascher, Andreas, Klein, Christian G., Neumann, Ulf Peter, Kroeger, Irena, Wimmer, Peter, Becker, Thomas, Guba, Markus, Mueller, Volker, Perrakis, Aristotelis, Klempnauer, Juergen, Lehner, Frank, Weiss, Karl Heinz, Pollok, Joerg-Matthias, Manekeller, Steffen, Nadalin, Silvio, Jonas, Sven, Bartels, Michael, Seehofer, Daniel, Tautenhahn, Hans- Michael, Schlitt, Hans Juergen, Heise, Michael, Kaiser, Gernot, Klein, Christian Georg, Moench, Christian, Ulrich, Frank, Schnitzbauer, Andreas, and Fischer, Lutz

Abstract

Liver transplantation 28(6), 998-1010 (2021). doi:10.1002/lt.26298, Published by Wiley, Hoboken, NJ

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results